Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578832 | 0.98 | SHMT2 (0.54) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL31578724 | 0.90 | SHMT2 (0.53) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL31578847 | 0.89 | CYP19A1 (0.58) | ALDH1A1KDM4EHPGDSHMT1CYP19A1 | |
| SCHEMBL31578626 | 0.88 | SHMT2 (0.64) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL31578780 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDSHMT1CYP19A1 | |
| SCHEMBL31578883 | 0.86 | SHMT2 (0.67) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL31578879 | 0.81 | SHMT2 (0.48) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL2075250 | 0.79 | ALDH1A1 (0.72) | ALDH1A1KDM4EHPGDCYP19A1MAOB | |
| SCHEMBL21560184 | 0.78 | ALDH1A1 (0.75) | SHMT2ALDH1A1KDM4EHPGDSHMT1 | |
| SCHEMBL31578670 | 0.78 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | KLHDC2, KLHL6, KLHL20 | SHMT2 1737/4885ALDH1A1 2481/4885KDM4E 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.